Journal of Clinical Pharmacy and Therapeutics
© John Wiley & Sons Ltd
Edited By: A. Li Wan Po
Impact Factor: 1.668
ISI Journal Citation Reports © Ranking: 2014: 171/255 (Pharmacology & Pharmacy)
Online ISSN: 1365-2710
Free review articles
Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs
Kawasaki disease: a comprehensive review of treatment options
Hyponatraemia induced by terlipressin: a case report and literature review
The role of abuse-deterrent formulations in countering opioid misuse and abuse
Inappropriate prescribing of intravenous fluid in adult inpatients-a literature review of current practice and research
Systematic review of topical amitriptyline for the treatment of neuropathic pain
Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma
Preserving the peritoneal membrane in long-term peritoneal dialysis patients
The role of azithromycin in healthcare-associated pneumonia treatment
Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection
Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions
Heme iron polypeptide for the management of anaemia of chronic kidney disease
Recently Published Articles
- Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature
K. L. Wallace, R. L. Filipek, R. M. La Hoz and J. C. Williamson
Version of Record online: 20 MAY 2016 | DOI: 10.1111/jcpt.12401
Subtherapeutic voriconazole concentrations due to an interaction with dexamethasone are not recognized by drug interaction databases. This interaction can have a significant impact on outcomes in patients with invasive fungal infections. The following case report discusses the clinical impact of a drug–drug interaction between dexamethasone and voriconazole and illustrates the time course of removal of the dexamethasone and the effect on voriconazole concentrations.
- Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis
K. R. Kaufman, K. M. Thurber, J. G. O'Meara, D. R. Langworthy and D. T. Kashiwagi
Version of Record online: 19 MAY 2016 | DOI: 10.1111/jcpt.12402
This was a single-centre, retrospective cohort analysis to determine if standard cephalexin dosing (500 mg QID) for management of cellulitis was associated with a difference in treatment failure for morbidly obese vs. non-obese patients. Failure rates were not statistically different, however fewer patients met inclusion and exclusion criteria than planned. Further studies with larger sample sizes and/or prospective design are needed.
- Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations (pages 310–328)
S. Vadcharavivad, S. Praisuwan, N. Techawathanawanna, W. Treyaprasert and Y. Avihingsanon
Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12396
Hemoglobin and duration of tacrolimus therapy could partly explain the interindividual variability of tacrolimus pharmacokinetics. A summary review of population pharmacokinetic models of twice daily tacrolimus in adult kidney transplant recipients is also provided.
- Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database (pages 368–370)
M. García, M. A. Aranburu, I. Palacios-Zabalza, U. Lertxundi and C. Aguirre
Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12397
Bullous pemphigoid has been associated with gliptins. We describe a case and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance (table ). The findings show a disproportionality for bullous pemphigoid and gliptins, except alogliptin (table ) and extend the evidence associating gliptins with this condition.
- Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects (pages 306–309)
H. Varela, E. Villamañán, C. Plasencia, J. A. Romero, M. Ruano, A. Balsa and A. Herrero
Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12393
Probability of treatment termination due to an adverse effect in terms of anti-TNF drug administered.